nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP2C9—Capecitabine—esophageal cancer	0.132	0.665	CbGbCtD
Dolasetron—CYP2C9—Cisplatin—esophageal cancer	0.0667	0.335	CbGbCtD
Dolasetron—Fluid overload—Carboplatin—esophageal cancer	0.03	0.0565	CcSEcCtD
Dolasetron—Phlebitis—Carboplatin—esophageal cancer	0.0157	0.0296	CcSEcCtD
Dolasetron—Atrial arrhythmia—Capecitabine—esophageal cancer	0.0145	0.0274	CcSEcCtD
Dolasetron—Shivering—Capecitabine—esophageal cancer	0.0108	0.0204	CcSEcCtD
Dolasetron—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.0104	0.0196	CcSEcCtD
Dolasetron—Prothrombin level increased—Capecitabine—esophageal cancer	0.00984	0.0185	CcSEcCtD
Dolasetron—Fluid overload—Cisplatin—esophageal cancer	0.00881	0.0166	CcSEcCtD
Dolasetron—Sneezing—Capecitabine—esophageal cancer	0.00729	0.0137	CcSEcCtD
Dolasetron—HTR3A—vagus nerve—esophageal cancer	0.00648	0.742	CbGeAlD
Dolasetron—Haematoma—Capecitabine—esophageal cancer	0.00642	0.0121	CcSEcCtD
Dolasetron—Intestinal obstruction—Capecitabine—esophageal cancer	0.00592	0.0111	CcSEcCtD
Dolasetron—Pain—Carboplatin—esophageal cancer	0.0057	0.0107	CcSEcCtD
Dolasetron—Hiccups—Cisplatin—esophageal cancer	0.00548	0.0103	CcSEcCtD
Dolasetron—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00527	0.00992	CcSEcCtD
Dolasetron—Body temperature increased—Carboplatin—esophageal cancer	0.00526	0.00991	CcSEcCtD
Dolasetron—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00502	0.00945	CcSEcCtD
Dolasetron—Injection site pain—Capecitabine—esophageal cancer	0.00494	0.00931	CcSEcCtD
Dolasetron—Extrasystoles—Capecitabine—esophageal cancer	0.0048	0.00903	CcSEcCtD
Dolasetron—Phlebitis—Cisplatin—esophageal cancer	0.00461	0.00869	CcSEcCtD
Dolasetron—Polyuria—Cisplatin—esophageal cancer	0.00453	0.00852	CcSEcCtD
Dolasetron—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00444	0.00836	CcSEcCtD
Dolasetron—Renal failure acute—Cisplatin—esophageal cancer	0.00431	0.00811	CcSEcCtD
Dolasetron—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00411	0.00773	CcSEcCtD
Dolasetron—Hiccups—Capecitabine—esophageal cancer	0.00404	0.0076	CcSEcCtD
Dolasetron—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00404	0.0076	CcSEcCtD
Dolasetron—Influenza like illness—Capecitabine—esophageal cancer	0.00392	0.00738	CcSEcCtD
Dolasetron—Face oedema—Cisplatin—esophageal cancer	0.00384	0.00722	CcSEcCtD
Dolasetron—Dehydration—Cisplatin—esophageal cancer	0.0037	0.00696	CcSEcCtD
Dolasetron—Urine output increased—Capecitabine—esophageal cancer	0.00365	0.00687	CcSEcCtD
Dolasetron—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00363	0.00683	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00358	0.00674	CcSEcCtD
Dolasetron—Abnormal vision—Capecitabine—esophageal cancer	0.00352	0.00663	CcSEcCtD
Dolasetron—Sepsis—Capecitabine—esophageal cancer	0.0035	0.00659	CcSEcCtD
Dolasetron—Phlebitis—Capecitabine—esophageal cancer	0.0034	0.0064	CcSEcCtD
Dolasetron—Thrombophlebitis—Capecitabine—esophageal cancer	0.00338	0.00637	CcSEcCtD
Dolasetron—Sleep disorder—Capecitabine—esophageal cancer	0.00338	0.00637	CcSEcCtD
Dolasetron—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00337	0.00634	CcSEcCtD
Dolasetron—Pancreatitis—Cisplatin—esophageal cancer	0.00337	0.00634	CcSEcCtD
Dolasetron—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00335	0.00631	CcSEcCtD
Dolasetron—Sweating increased—Cisplatin—esophageal cancer	0.00335	0.0063	CcSEcCtD
Dolasetron—Polyuria—Capecitabine—esophageal cancer	0.00334	0.00628	CcSEcCtD
Dolasetron—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.0033	0.00622	CcSEcCtD
Dolasetron—Vascular purpura—Capecitabine—esophageal cancer	0.00328	0.00617	CcSEcCtD
Dolasetron—Oliguria—Methotrexate—esophageal cancer	0.00326	0.00614	CcSEcCtD
Dolasetron—Renal failure acute—Capecitabine—esophageal cancer	0.00317	0.00597	CcSEcCtD
Dolasetron—Increased appetite—Capecitabine—esophageal cancer	0.00312	0.00587	CcSEcCtD
Dolasetron—Purpura—Capecitabine—esophageal cancer	0.00304	0.00572	CcSEcCtD
Dolasetron—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00302	0.00568	CcSEcCtD
Dolasetron—Myocardial infarction—Cisplatin—esophageal cancer	0.003	0.00565	CcSEcCtD
Dolasetron—Stomatitis—Cisplatin—esophageal cancer	0.00299	0.00562	CcSEcCtD
Dolasetron—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.00285	0.0109	CbGpPWpGaD
Dolasetron—Face oedema—Capecitabine—esophageal cancer	0.00283	0.00533	CcSEcCtD
Dolasetron—Aplastic anaemia—Methotrexate—esophageal cancer	0.00282	0.00531	CcSEcCtD
Dolasetron—Bradycardia—Cisplatin—esophageal cancer	0.0028	0.00527	CcSEcCtD
Dolasetron—Cardiac arrest—Capecitabine—esophageal cancer	0.00279	0.00525	CcSEcCtD
Dolasetron—Urinary retention—Capecitabine—esophageal cancer	0.00279	0.00525	CcSEcCtD
Dolasetron—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00277	0.0106	CbGpPWpGaD
Dolasetron—Ataxia—Capecitabine—esophageal cancer	0.00275	0.00519	CcSEcCtD
Dolasetron—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00274	0.0105	CbGpPWpGaD
Dolasetron—Dehydration—Capecitabine—esophageal cancer	0.00272	0.00513	CcSEcCtD
Dolasetron—Urine output increased—Methotrexate—esophageal cancer	0.00272	0.00511	CcSEcCtD
Dolasetron—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00268	0.0103	CbGpPWpGaD
Dolasetron—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00268	0.00504	CcSEcCtD
Dolasetron—Visual impairment—Cisplatin—esophageal cancer	0.00265	0.00499	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00264	0.00497	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00262	0.01	CbGpPWpGaD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00262	0.01	CbGpPWpGaD
Dolasetron—Sepsis—Methotrexate—esophageal cancer	0.00261	0.00491	CcSEcCtD
Dolasetron—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.0026	0.00995	CbGpPWpGaD
Dolasetron—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00258	0.00487	CcSEcCtD
Dolasetron—Tinnitus—Cisplatin—esophageal cancer	0.00256	0.00483	CcSEcCtD
Dolasetron—Flushing—Cisplatin—esophageal cancer	0.00255	0.0048	CcSEcCtD
Dolasetron—Abdominal distension—Capecitabine—esophageal cancer	0.00255	0.0048	CcSEcCtD
Dolasetron—Thrombophlebitis—Methotrexate—esophageal cancer	0.00252	0.00474	CcSEcCtD
Dolasetron—Bronchospasm—Capecitabine—esophageal cancer	0.00249	0.00469	CcSEcCtD
Dolasetron—Polyuria—Methotrexate—esophageal cancer	0.00248	0.00468	CcSEcCtD
Dolasetron—Sweating increased—Capecitabine—esophageal cancer	0.00247	0.00464	CcSEcCtD
Dolasetron—Arrhythmia—Cisplatin—esophageal cancer	0.00246	0.00462	CcSEcCtD
Dolasetron—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00245	0.00938	CbGpPWpGaD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00239	0.00916	CbGpPWpGaD
Dolasetron—Dysuria—Capecitabine—esophageal cancer	0.00237	0.00446	CcSEcCtD
Dolasetron—Renal failure acute—Methotrexate—esophageal cancer	0.00236	0.00445	CcSEcCtD
Dolasetron—Flatulence—Cisplatin—esophageal cancer	0.00236	0.00444	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00233	0.00894	CbGpPWpGaD
Dolasetron—Pneumonia—Capecitabine—esophageal cancer	0.00227	0.00428	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00226	0.00865	CbGpPWpGaD
Dolasetron—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00225	0.00424	CcSEcCtD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00225	0.00861	CbGpPWpGaD
Dolasetron—Tremor—Cisplatin—esophageal cancer	0.00224	0.00422	CcSEcCtD
Dolasetron—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00223	0.00854	CbGpPWpGaD
Dolasetron—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00223	0.00419	CcSEcCtD
Dolasetron—Ill-defined disorder—Cisplatin—esophageal cancer	0.00222	0.00418	CcSEcCtD
Dolasetron—Myocardial infarction—Capecitabine—esophageal cancer	0.00221	0.00417	CcSEcCtD
Dolasetron—Anaemia—Cisplatin—esophageal cancer	0.00221	0.00417	CcSEcCtD
Dolasetron—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00221	0.00847	CbGpPWpGaD
Dolasetron—Jaundice—Capecitabine—esophageal cancer	0.0022	0.00414	CcSEcCtD
Dolasetron—Stomatitis—Capecitabine—esophageal cancer	0.0022	0.00414	CcSEcCtD
Dolasetron—Malaise—Cisplatin—esophageal cancer	0.00216	0.00406	CcSEcCtD
Dolasetron—Haematuria—Capecitabine—esophageal cancer	0.00215	0.00405	CcSEcCtD
Dolasetron—Epistaxis—Capecitabine—esophageal cancer	0.00213	0.00401	CcSEcCtD
Dolasetron—Convulsion—Cisplatin—esophageal cancer	0.00207	0.0039	CcSEcCtD
Dolasetron—Bradycardia—Capecitabine—esophageal cancer	0.00206	0.00388	CcSEcCtD
Dolasetron—Ataxia—Methotrexate—esophageal cancer	0.00205	0.00386	CcSEcCtD
Dolasetron—Myalgia—Cisplatin—esophageal cancer	0.00204	0.00384	CcSEcCtD
Dolasetron—Anxiety—Cisplatin—esophageal cancer	0.00203	0.00382	CcSEcCtD
Dolasetron—Discomfort—Cisplatin—esophageal cancer	0.00201	0.00379	CcSEcCtD
Dolasetron—Oedema peripheral—Capecitabine—esophageal cancer	0.002	0.00376	CcSEcCtD
Dolasetron—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00196	0.0075	CbGpPWpGaD
Dolasetron—Oedema—Cisplatin—esophageal cancer	0.00195	0.00368	CcSEcCtD
Dolasetron—Anaphylactic shock—Cisplatin—esophageal cancer	0.00195	0.00368	CcSEcCtD
Dolasetron—Visual impairment—Capecitabine—esophageal cancer	0.00195	0.00368	CcSEcCtD
Dolasetron—Thrombocytopenia—Cisplatin—esophageal cancer	0.00191	0.0036	CcSEcCtD
Dolasetron—Tachycardia—Cisplatin—esophageal cancer	0.00191	0.00359	CcSEcCtD
Dolasetron—Tinnitus—Capecitabine—esophageal cancer	0.00189	0.00356	CcSEcCtD
Dolasetron—Hyperhidrosis—Cisplatin—esophageal cancer	0.00189	0.00356	CcSEcCtD
Dolasetron—Flushing—Capecitabine—esophageal cancer	0.00188	0.00354	CcSEcCtD
Dolasetron—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00188	0.0072	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00187	0.00718	CbGpPWpGaD
Dolasetron—Anorexia—Cisplatin—esophageal cancer	0.00186	0.00351	CcSEcCtD
Dolasetron—Pancreatitis—Methotrexate—esophageal cancer	0.00185	0.00348	CcSEcCtD
Dolasetron—Hypotension—Cisplatin—esophageal cancer	0.00183	0.00344	CcSEcCtD
Dolasetron—Chills—Capecitabine—esophageal cancer	0.00182	0.00342	CcSEcCtD
Dolasetron—Arrhythmia—Capecitabine—esophageal cancer	0.00181	0.00341	CcSEcCtD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00181	0.00693	CbGpPWpGaD
Dolasetron—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00178	0.00335	CcSEcCtD
Dolasetron—Dysuria—Methotrexate—esophageal cancer	0.00176	0.00332	CcSEcCtD
Dolasetron—Paraesthesia—Cisplatin—esophageal cancer	0.00175	0.0033	CcSEcCtD
Dolasetron—Dyspnoea—Cisplatin—esophageal cancer	0.00174	0.00328	CcSEcCtD
Dolasetron—Flatulence—Capecitabine—esophageal cancer	0.00174	0.00327	CcSEcCtD
Dolasetron—Dysgeusia—Capecitabine—esophageal cancer	0.00173	0.00325	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00173	0.00661	CbGpPWpGaD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00173	0.00661	CbGpPWpGaD
Dolasetron—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00172	0.0066	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00171	0.00654	CbGpPWpGaD
Dolasetron—Decreased appetite—Cisplatin—esophageal cancer	0.0017	0.0032	CcSEcCtD
Dolasetron—Pneumonia—Methotrexate—esophageal cancer	0.00169	0.00318	CcSEcCtD
Dolasetron—Drowsiness—Methotrexate—esophageal cancer	0.00168	0.00316	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00168	0.00642	CbGpPWpGaD
Dolasetron—Pain—Cisplatin—esophageal cancer	0.00167	0.00315	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00167	0.00639	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00166	0.00637	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00165	0.00634	CbGpPWpGaD
Dolasetron—Tremor—Capecitabine—esophageal cancer	0.00165	0.00311	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00165	0.00633	CbGpPWpGaD
Dolasetron—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00165	0.00632	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00164	0.00628	CbGpPWpGaD
Dolasetron—Stomatitis—Methotrexate—esophageal cancer	0.00164	0.00308	CcSEcCtD
Dolasetron—Ill-defined disorder—Capecitabine—esophageal cancer	0.00164	0.00308	CcSEcCtD
Dolasetron—Anaemia—Capecitabine—esophageal cancer	0.00163	0.00307	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00162	0.00619	CbGpPWpGaD
Dolasetron—Feeling abnormal—Cisplatin—esophageal cancer	0.00161	0.00303	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00161	0.00615	CbGpPWpGaD
Dolasetron—Haematuria—Methotrexate—esophageal cancer	0.0016	0.00302	CcSEcCtD
Dolasetron—Malaise—Capecitabine—esophageal cancer	0.00159	0.003	CcSEcCtD
Dolasetron—Epistaxis—Methotrexate—esophageal cancer	0.00159	0.00298	CcSEcCtD
Dolasetron—Vertigo—Capecitabine—esophageal cancer	0.00159	0.00298	CcSEcCtD
Dolasetron—Syncope—Capecitabine—esophageal cancer	0.00158	0.00298	CcSEcCtD
Dolasetron—Palpitations—Capecitabine—esophageal cancer	0.00156	0.00294	CcSEcCtD
Dolasetron—Loss of consciousness—Capecitabine—esophageal cancer	0.00155	0.00292	CcSEcCtD
Dolasetron—Body temperature increased—Cisplatin—esophageal cancer	0.00154	0.00291	CcSEcCtD
Dolasetron—Cough—Capecitabine—esophageal cancer	0.00154	0.0029	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00154	0.00589	CbGpPWpGaD
Dolasetron—Hypertension—Capecitabine—esophageal cancer	0.00152	0.00287	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00152	0.00583	CbGpPWpGaD
Dolasetron—Arthralgia—Capecitabine—esophageal cancer	0.0015	0.00283	CcSEcCtD
Dolasetron—Chest pain—Capecitabine—esophageal cancer	0.0015	0.00283	CcSEcCtD
Dolasetron—Myalgia—Capecitabine—esophageal cancer	0.0015	0.00283	CcSEcCtD
Dolasetron—Anxiety—Capecitabine—esophageal cancer	0.0015	0.00282	CcSEcCtD
Dolasetron—Discomfort—Capecitabine—esophageal cancer	0.00148	0.00279	CcSEcCtD
Dolasetron—Dry mouth—Capecitabine—esophageal cancer	0.00147	0.00277	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00146	0.0056	CbGpPWpGaD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00146	0.00559	CbGpPWpGaD
Dolasetron—Visual impairment—Methotrexate—esophageal cancer	0.00145	0.00274	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00145	0.00556	CbGpPWpGaD
Dolasetron—Confusional state—Capecitabine—esophageal cancer	0.00145	0.00273	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00145	0.00555	CbGpPWpGaD
Dolasetron—Oedema—Capecitabine—esophageal cancer	0.00144	0.00271	CcSEcCtD
Dolasetron—Hypersensitivity—Cisplatin—esophageal cancer	0.00144	0.00271	CcSEcCtD
Dolasetron—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00142	0.00545	CbGpPWpGaD
Dolasetron—Shock—Capecitabine—esophageal cancer	0.00142	0.00267	CcSEcCtD
Dolasetron—Thrombocytopenia—Capecitabine—esophageal cancer	0.00141	0.00265	CcSEcCtD
Dolasetron—Tinnitus—Methotrexate—esophageal cancer	0.00141	0.00265	CcSEcCtD
Dolasetron—Tachycardia—Capecitabine—esophageal cancer	0.00141	0.00265	CcSEcCtD
Dolasetron—Asthenia—Cisplatin—esophageal cancer	0.0014	0.00264	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00139	0.00533	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00139	0.00533	CbGpPWpGaD
Dolasetron—Hyperhidrosis—Capecitabine—esophageal cancer	0.00139	0.00262	CcSEcCtD
Dolasetron—Anorexia—Capecitabine—esophageal cancer	0.00137	0.00258	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00136	0.00521	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00136	0.0052	CbGpPWpGaD
Dolasetron—Chills—Methotrexate—esophageal cancer	0.00135	0.00255	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00135	0.00516	CbGpPWpGaD
Dolasetron—Hypotension—Capecitabine—esophageal cancer	0.00135	0.00253	CcSEcCtD
Dolasetron—Diarrhoea—Cisplatin—esophageal cancer	0.00134	0.00252	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00131	0.00247	CcSEcCtD
Dolasetron—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.0013	0.00498	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.0013	0.00498	CbGpPWpGaD
Dolasetron—Paraesthesia—Capecitabine—esophageal cancer	0.00129	0.00243	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00129	0.00495	CbGpPWpGaD
Dolasetron—Dysgeusia—Methotrexate—esophageal cancer	0.00129	0.00242	CcSEcCtD
Dolasetron—Dyspnoea—Capecitabine—esophageal cancer	0.00128	0.00242	CcSEcCtD
Dolasetron—Dyspepsia—Capecitabine—esophageal cancer	0.00127	0.00239	CcSEcCtD
Dolasetron—Decreased appetite—Capecitabine—esophageal cancer	0.00125	0.00236	CcSEcCtD
Dolasetron—Fatigue—Capecitabine—esophageal cancer	0.00124	0.00234	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00124	0.00474	CbGpPWpGaD
Dolasetron—Rash—Cisplatin—esophageal cancer	0.00123	0.00232	CcSEcCtD
Dolasetron—Constipation—Capecitabine—esophageal cancer	0.00123	0.00232	CcSEcCtD
Dolasetron—Pain—Capecitabine—esophageal cancer	0.00123	0.00232	CcSEcCtD
Dolasetron—Dermatitis—Cisplatin—esophageal cancer	0.00123	0.00232	CcSEcCtD
Dolasetron—Ill-defined disorder—Methotrexate—esophageal cancer	0.00122	0.00229	CcSEcCtD
Dolasetron—Anaemia—Methotrexate—esophageal cancer	0.00121	0.00229	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00119	0.00458	CbGpPWpGaD
Dolasetron—Feeling abnormal—Capecitabine—esophageal cancer	0.00119	0.00223	CcSEcCtD
Dolasetron—Malaise—Methotrexate—esophageal cancer	0.00118	0.00223	CcSEcCtD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00118	0.00454	CbGpPWpGaD
Dolasetron—Vertigo—Methotrexate—esophageal cancer	0.00118	0.00222	CcSEcCtD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00118	0.00452	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00118	0.00222	CcSEcCtD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00117	0.00448	CbGpPWpGaD
Dolasetron—Cough—Methotrexate—esophageal cancer	0.00115	0.00216	CcSEcCtD
Dolasetron—Urticaria—Capecitabine—esophageal cancer	0.00114	0.00215	CcSEcCtD
Dolasetron—Body temperature increased—Capecitabine—esophageal cancer	0.00114	0.00214	CcSEcCtD
Dolasetron—Abdominal pain—Capecitabine—esophageal cancer	0.00114	0.00214	CcSEcCtD
Dolasetron—Convulsion—Methotrexate—esophageal cancer	0.00114	0.00214	CcSEcCtD
Dolasetron—Chest pain—Methotrexate—esophageal cancer	0.00112	0.00211	CcSEcCtD
Dolasetron—Arthralgia—Methotrexate—esophageal cancer	0.00112	0.00211	CcSEcCtD
Dolasetron—Myalgia—Methotrexate—esophageal cancer	0.00112	0.00211	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00111	0.00424	CbGpPWpGaD
Dolasetron—Discomfort—Methotrexate—esophageal cancer	0.0011	0.00208	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.0011	0.00423	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.0011	0.0042	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00109	0.00418	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00108	0.00414	CbGpPWpGaD
Dolasetron—Confusional state—Methotrexate—esophageal cancer	0.00108	0.00204	CcSEcCtD
Dolasetron—Anaphylactic shock—Methotrexate—esophageal cancer	0.00107	0.00202	CcSEcCtD
Dolasetron—Hypersensitivity—Capecitabine—esophageal cancer	0.00106	0.002	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00106	0.00404	CbGpPWpGaD
Dolasetron—Thrombocytopenia—Methotrexate—esophageal cancer	0.00105	0.00198	CcSEcCtD
Dolasetron—Hyperhidrosis—Methotrexate—esophageal cancer	0.00104	0.00195	CcSEcCtD
Dolasetron—Asthenia—Capecitabine—esophageal cancer	0.00103	0.00195	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00103	0.00395	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00103	0.00394	CbGpPWpGaD
Dolasetron—Anorexia—Methotrexate—esophageal cancer	0.00102	0.00192	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00102	0.00391	CbGpPWpGaD
Dolasetron—Pruritus—Capecitabine—esophageal cancer	0.00102	0.00192	CcSEcCtD
Dolasetron—Hypotension—Methotrexate—esophageal cancer	0.001	0.00189	CcSEcCtD
Dolasetron—Diarrhoea—Capecitabine—esophageal cancer	0.000985	0.00186	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000977	0.00184	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000968	0.00371	CbGpPWpGaD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000963	0.00369	CbGpPWpGaD
Dolasetron—Paraesthesia—Methotrexate—esophageal cancer	0.000963	0.00181	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00096	0.00368	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000957	0.00367	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000956	0.00366	CbGpPWpGaD
Dolasetron—Dyspnoea—Methotrexate—esophageal cancer	0.000956	0.0018	CcSEcCtD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000955	0.00366	CbGpPWpGaD
Dolasetron—Somnolence—Methotrexate—esophageal cancer	0.000953	0.00179	CcSEcCtD
Dolasetron—Dizziness—Capecitabine—esophageal cancer	0.000952	0.00179	CcSEcCtD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00095	0.00364	CbGpPWpGaD
Dolasetron—Dyspepsia—Methotrexate—esophageal cancer	0.000944	0.00178	CcSEcCtD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000942	0.00361	CbGpPWpGaD
Dolasetron—Decreased appetite—Methotrexate—esophageal cancer	0.000932	0.00175	CcSEcCtD
Dolasetron—Fatigue—Methotrexate—esophageal cancer	0.000924	0.00174	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000918	0.00352	CbGpPWpGaD
Dolasetron—Pain—Methotrexate—esophageal cancer	0.000917	0.00173	CcSEcCtD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00091	0.00349	CbGpPWpGaD
Dolasetron—Rash—Capecitabine—esophageal cancer	0.000908	0.00171	CcSEcCtD
Dolasetron—Dermatitis—Capecitabine—esophageal cancer	0.000907	0.00171	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000905	0.00347	CbGpPWpGaD
Dolasetron—Headache—Capecitabine—esophageal cancer	0.000902	0.0017	CcSEcCtD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000898	0.00344	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000893	0.00342	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000889	0.0034	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000886	0.00339	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000886	0.00339	CbGpPWpGaD
Dolasetron—Feeling abnormal—Methotrexate—esophageal cancer	0.000883	0.00166	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000878	0.00336	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000877	0.00165	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000857	0.00328	CbGpPWpGaD
Dolasetron—Urticaria—Methotrexate—esophageal cancer	0.000852	0.0016	CcSEcCtD
Dolasetron—Abdominal pain—Methotrexate—esophageal cancer	0.000847	0.0016	CcSEcCtD
Dolasetron—Body temperature increased—Methotrexate—esophageal cancer	0.000847	0.0016	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000817	0.00313	CbGpPWpGaD
Dolasetron—Hypersensitivity—Methotrexate—esophageal cancer	0.00079	0.00149	CcSEcCtD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000781	0.00299	CbGpPWpGaD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000781	0.00299	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000779	0.00298	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000777	0.00297	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000774	0.00296	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000771	0.00295	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.00077	0.00295	CbGpPWpGaD
Dolasetron—Asthenia—Methotrexate—esophageal cancer	0.000769	0.00145	CcSEcCtD
Dolasetron—Pruritus—Methotrexate—esophageal cancer	0.000758	0.00143	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000755	0.00289	CbGpPWpGaD
Dolasetron—HTR3A—digestive system—esophageal cancer	0.000736	0.0842	CbGeAlD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000734	0.00281	CbGpPWpGaD
Dolasetron—Diarrhoea—Methotrexate—esophageal cancer	0.000733	0.00138	CcSEcCtD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000732	0.0028	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000728	0.00279	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000722	0.00277	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000716	0.00274	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000712	0.00273	CbGpPWpGaD
Dolasetron—Dizziness—Methotrexate—esophageal cancer	0.000709	0.00133	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000706	0.0027	CbGpPWpGaD
Dolasetron—Rash—Methotrexate—esophageal cancer	0.000676	0.00127	CcSEcCtD
Dolasetron—Dermatitis—Methotrexate—esophageal cancer	0.000675	0.00127	CcSEcCtD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000673	0.00258	CbGpPWpGaD
Dolasetron—Headache—Methotrexate—esophageal cancer	0.000672	0.00126	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000671	0.00257	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000665	0.00255	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000662	0.00254	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000656	0.00251	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000633	0.00243	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00063	0.00241	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000621	0.00238	CbGpPWpGaD
Dolasetron—HTR3A—lung—esophageal cancer	0.000615	0.0703	CbGeAlD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0006	0.0023	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000592	0.00227	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000584	0.00224	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000583	0.00223	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000579	0.00222	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00056	0.00214	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000547	0.0021	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000542	0.00208	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00052	0.00199	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000516	0.00198	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000514	0.00197	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00051	0.00195	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.00051	0.00195	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000508	0.00194	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000498	0.00191	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000488	0.00187	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000483	0.00185	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00048	0.00184	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000472	0.00181	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000466	0.00178	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000439	0.00168	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000433	0.00166	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000415	0.00159	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000411	0.00157	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000409	0.00157	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000405	0.00155	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000397	0.00152	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.00039	0.00149	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000387	0.00148	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000385	0.00147	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000381	0.00146	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000374	0.00143	CbGpPWpGaD
Dolasetron—CYP2C9—digestive system—esophageal cancer	0.00036	0.0413	CbGeAlD
Dolasetron—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000358	0.00137	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.00034	0.0013	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000336	0.00129	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000319	0.00122	CbGpPWpGaD
Dolasetron—CYP3A4—digestive system—esophageal cancer	0.000275	0.0315	CbGeAlD
Dolasetron—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000271	0.00104	CbGpPWpGaD
Dolasetron—CYP2D6—digestive system—esophageal cancer	0.00027	0.031	CbGeAlD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000268	0.00103	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000267	0.00102	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000255	0.000976	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000251	0.000963	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000234	0.000895	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000209	0.000802	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000209	0.000802	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000208	0.000795	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000208	0.000795	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000186	0.000711	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CA1—esophageal cancer	0.000178	0.000682	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000178	0.000682	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000177	0.000676	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CA1—esophageal cancer	0.000177	0.000676	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CA2—esophageal cancer	0.000163	0.000624	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CA2—esophageal cancer	0.000162	0.000619	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000158	0.000605	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000151	0.00058	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000151	0.00058	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.00015	0.000575	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ADH7—esophageal cancer	0.00015	0.000575	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000148	0.000568	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000137	0.000525	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000137	0.000525	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000133	0.000509	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000132	0.000504	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000127	0.000486	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000126	0.000482	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000123	0.000473	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000122	0.000469	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.00012	0.000461	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000119	0.000457	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CA1—esophageal cancer	0.000116	0.000446	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000116	0.000446	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000115	0.00044	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000115	0.00044	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000114	0.000436	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000114	0.000436	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.00011	0.000422	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000109	0.000418	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CA2—esophageal cancer	0.000107	0.000408	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000106	0.000406	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.000105	0.000402	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000105	0.000402	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.000104	0.000399	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GNG7—esophageal cancer	9.99e-05	0.000382	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ADH7—esophageal cancer	9.9e-05	0.000379	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.9e-05	0.000379	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GNG7—esophageal cancer	9.9e-05	0.000379	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.36e-05	0.000358	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALDH2—esophageal cancer	9.28e-05	0.000355	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTT1—esophageal cancer	8.9e-05	0.000341	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.82e-05	0.000338	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.8e-05	0.000337	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2A6—esophageal cancer	8.72e-05	0.000334	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.69e-05	0.000333	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.68e-05	0.000333	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ENO1—esophageal cancer	8.34e-05	0.000319	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.34e-05	0.000319	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TYMP—esophageal cancer	8.3e-05	0.000318	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTGS1—esophageal cancer	8.27e-05	0.000317	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ENO1—esophageal cancer	8.27e-05	0.000317	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PSME2—esophageal cancer	8.22e-05	0.000315	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PSME1—esophageal cancer	8.22e-05	0.000315	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PSME2—esophageal cancer	8.15e-05	0.000312	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PSME1—esophageal cancer	8.15e-05	0.000312	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.07e-05	0.000309	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.87e-05	0.000301	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TPI1—esophageal cancer	7.5e-05	0.000287	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.5e-05	0.000287	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.2e-05	0.000276	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.11e-05	0.000273	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.09e-05	0.000272	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1B1—esophageal cancer	7.03e-05	0.000269	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.93e-05	0.000265	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.86e-05	0.000263	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.67e-05	0.000255	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.61e-05	0.000253	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GNG7—esophageal cancer	6.53e-05	0.00025	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.12e-05	0.000234	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.08e-05	0.000233	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HMOX1—esophageal cancer	6.03e-05	0.000231	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.92e-05	0.000227	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.84e-05	0.000224	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.82e-05	0.000223	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.79e-05	0.000222	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.75e-05	0.00022	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.45e-05	0.000209	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ENO1—esophageal cancer	5.45e-05	0.000209	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PSME2—esophageal cancer	5.37e-05	0.000206	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PSME1—esophageal cancer	5.37e-05	0.000206	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.64e-05	0.000178	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.38e-05	0.000168	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.36e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.98e-05	0.000152	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.9e-05	0.000149	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.87e-05	0.000148	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.82e-05	0.000146	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NOS3—esophageal cancer	3.49e-05	0.000134	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NOS3—esophageal cancer	3.46e-05	0.000133	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.2e-05	0.000122	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.17e-05	0.000121	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—EP300—esophageal cancer	2.66e-05	0.000102	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—EP300—esophageal cancer	2.64e-05	0.000101	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.55e-05	9.77e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NOS3—esophageal cancer	2.28e-05	8.75e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.09e-05	8e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.97e-05	7.53e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.95e-05	7.47e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—EP300—esophageal cancer	1.74e-05	6.66e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.29e-05	4.92e-05	CbGpPWpGaD
